MET Inhibition in Metastatic NSCLC In the Spotlight
Host: Paul Paik, MD
\n\n Guest: D. Ross Camidge, MD, PhD
\n\n Guest: Keith Kerr, BSc, MB ChB
\n\n\n \n
Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we\u2019re learning to everyday clinical practice.